

## ASX ANNOUNCEMENT

### Vitura completes acquisition of Canview platform

26 FEBRUARY 2025

**Melbourne, Australia** – Vitura Health Limited (ASX: VIT) (**Vitura and Company**), a leading digital health platform business focused on innovating the delivery of healthcare by building a centralised healthcare experience, is pleased to announce that it has finalised the acquisition of a complete copy of the software, data and all related materials underlying the Company’s “Canview” platform (**Copy**).

As detailed in its previous announcement dated 17 October 2024 (**Previous Announcement**), Vitura executed a Settlement Agreement to settle its dispute with software developer Code4 Cannabis Pty Ltd (**C4C**) pursuant to which, amongst other things, Vitura’s wholly-owned subsidiary, Canview Pty Ltd (**Canview**), would, subject to the matters set out in the Previous Announcement, acquire the Copy from C4C. The Copy has now been acquired and established in the Company’s own environment, such that Vitura will own, operate and develop its Copy of the platform going forward. This is expected to enable the Company to rapidly expand its technology stack with less risk and in a far more cost-effective way, in line with the platform functionality required to deliver the Company’s *Strategy Reset*.

Certification under the Settlement Agreement occurred on 21 February 2025. As foreshadowed in the Previous Announcement, following Certification being granted, the Company has now issued 5,787,037 ordinary shares in Vitura (being the equivalent of \$500,000 worth of Vitura ordinary shares at a price equal to the volume weighted average price of Vitura’s shares for the five trading days immediately preceding the date of the Settlement Agreement, being \$0.0864 per share). The Company has also paid to C4C the remainder of the \$2.5 million cash payment in accordance with the terms of the Settlement Agreement. Further, as foreshadowed in the Previous Announcement, the Vitura group will now take steps to withdraw all legal proceedings against C4C.

Canview has now been granted property in the Copy enabling it to exploit, modify, use or otherwise deal with the Copy and an irrevocable licence to use, modify and sublicense the Copy. Canview will not, however, be able to sell further copies of the Copy to any third party for a period of 12 months from the date of the Settlement Agreement. As previously advised, the Services Agreement between C4C and Canview, which was due to terminate in November 2025, has now been terminated and the fees previously paid to C4C by Canview, amounting to approximately \$100,000 per month, have ceased.

Finally, C4C is restrained from using, exploiting or dealing with the platform for a period nine months from the date of Certification and for a period of 12 months in the case of any party operating in the medicinal cannabis or nicotine industries.

In commenting on the Company’s acquisition of the Copy, Vitura’s CEO, Geoff Cockerill, said: *“We are very pleased to be able to now have complete control of the future operation and development of our market-leading Canview platform. We remain confident that we are well positioned to introduce a number of valuable new products and features on the platform that will excite our customers and further secure our position as a leading player in our space, enabling us to deliver on our Strategy Reset”.*

\*\* ENDS \*\*

VITURA HEALTH LIMITED

ASX: VIT

PO Box 6168, South Yarra

Victoria 3141, Australia

VITURA.COM.AU





## About Vitura Health Limited (ASX: VIT)

[www.vitura.com.au](http://www.vitura.com.au)

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- [www.burleighheadscannabis.com](http://www.burleighheadscannabis.com)  
Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes 430+ therapeutic product and device SKUs within Australia from roughly 60 international and domestic brands.
- [www.canview.com.au](http://www.canview.com.au)  
Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the nearly 4,500 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- [www.doctorsondemand.com.au](http://www.doctorsondemand.com.au)  
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.
- [www.cortexa.com.au](http://www.cortexa.com.au)  
The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- [www.cdaclinics.com.au](http://www.cdaclinics.com.au)  
The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- [www.cannadoc.com.au](http://www.cannadoc.com.au)  
The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

**Authorised by**

Robert Iervasi, Chair and Non-Executive Director

**Contact****Vitura Health Limited**

Robert Iervasi

Chair

1300 799 491

[info@vitura.com.au](mailto:info@vitura.com.au)

**Media enquiries**

Dieter Lehmann

Nominis Communications

+61 427 672 995

[dieter@nominis.me](mailto:dieter@nominis.me)

**Forward-looking statements**

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.